Table 1.
Clinical features and number of myocardial infarction (MI) and strokes reported in each clinical trial
| Trial | Study Drug | Number of PCSK treated | Number of controls | Age | DM (%) | HT (%) | Smoking (%) | Number of MI | Number of strokes | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Treated | Controls | Treated | Controls | ||||||||
| OSLER I-II | Evolocumab | 2976 | 1489 | 58.1 | 13.0 | 52 | 15.5 | 9 | 5 | 1 | 3 |
| ODYSSEY Long Term | Alirocumab | 1553 | 788 | 60.4 | 34.5 | - | 20.5 | 14 | 18 | 9 | 2 |
| Glagov | Evolocumab | 484 | 484 | 59.8 | 20.5 | 83 | 23.3 | 1 | 14 | 2 | 3 |
| FOURIER | Evolocumab | 13784 | 13780 | 62.5 | 36.5 | 80.0 | 28.3 | 468 | 639 | 207 | 262 |
| SPIRE I-II | Bococizumab | 13720 | 13718 | 63.3 | 47.5 | 80.8 | 24.5 | 192 | 210 | 45 | 75 |
| ODYSSEY | Alirocumab | 9462 | 9462 | 58.5 | 29.0 | 65.0 | 24.0 | 626 | 722 | 111 | 152 |
| Total: | 41,979 | 39,721 | 60.5 | 32.1 | 69.5 | 22.6 | 1,319 | 1,608 | 375 | 497 | |
DM; diabetes mellitus; HT: hypertension